argenx SE

Below you will find information from the register publication of inside information. The information has been provided by the organisation.

  • Registration date 06 jun 2018 - 07:00
  • Statutory name argenx SE
  • Title argenx receives feedback from FDA in end-of-phase 2 meeting for efgartigimod in myasthenia gravis

Related downloads

201806060000000001_argenx receives feedback from FDA in end.pdf

Date last update: 12 December 2019

Share information

Share on: Share this